Citius Pharmaceuticals, Inc. 8K

Citius Oncology reported accelerating commercial uptake and broadening market access for its CTCL therapy LYMPHIR, with significant quarter-over-quarter growth in ordering institutions and payer coverage as of mid-2026.

On August 5, 2026, Citius Oncology, Inc. (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), issued a press release providing a commercial update on LYMPHIR (denileukin diftitox-cxdl), highlighting strong launch momentum including a 78% quarter-over-quarter increase in new institutional accounts ordering the drug, a 31% rise in institutional vial orders for the quarter ended June 30, 2026, growing formulary inclusion at priority U.S. treatment centers, and near-universal payer coverage that together support broader market access and an estimated initial CTCL market opportunity exceeding $400 million.

Filing Facts

CIK

1506251

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-085432

Alert Tier

6